In this video, Dr. Samuel Klempner, MD summarizes the phase 3 STAR-221 clinical trial investigating a novel treatment for advanced upper gastrointestinal cancers.
The STAR-221 study is comparing the combination of the immunotherapies domvanalimab, zimberelimab, and chemotherapy against standard chemotherapy plus nivolumab. It is enrolling over 700 patients with untreated, metastatic gastric, GE junction, or esophageal adenocarcinoma.
The co-primary endpoints are progression-free and overall survival. Key secondary endpoints include response rate, duration of response, and safety. Dr. Klempner provides high-level overviews of the preliminary efficacy and safety data from the trial.
He also discusses how PD-L1 expression is being analyzed to determine which patients may benefit most from this combination immunotherapy approach.
This concise overview summarizes the STAR-221 trial’s important research into improving outcomes for difficult-to-treat upper gastrointestinal cancers like gastric, ES junction, and esophageal adenocarcinomas.
Learn more about Dr. Klempner’s work in developmental therapeutics for gastrointestinal cancers.